MacroGenics (MGNX) Earnings Date & Reports

Key Takeaways

• MacroGenics is expected to report Q2 2026 results around August 13, 2026, before the market opens, though the company has not yet confirmed the exact date.
• Analyst estimates for Q2 2026 show unusually wide dispersion: consensus revenue forecasts range from approximately $59 million to $68 million, while EPS (earnings per share) estimates span from -$0.34 to +$0.26, reflecting high uncertainty tied to milestone and collaboration revenue timing.
• Q1 2026 revenue of $20.78 million beat expectations by roughly 36%, but EPS of -$0.58 narrowly missed consensus; the stock rallied approximately 20% following the report.
• The planned manufacturing divestiture to Bora Pharmaceuticals for $122.5 million, expected to close in Q3 2026, and a recently received $60 million payment from Sagard are poised to meaningfully strengthen the company's balance sheet.
• MacroGenics has guided for a cash runway through 2028, supported by its $154.2 million cash position as of March 31, 2026, plus anticipated partnership and divestiture proceeds.

Earnings Context and Why It Matters

MacroGenics (NASDAQ: MGNX) enters its Q2 2026 earnings report at a pivotal moment. The clinical-stage biopharmaceutical company, which develops antibody-based cancer therapeutics, is navigating a business transformation that includes the divestiture of its manufacturing operations to focus more intently on its pipeline. With the stock up over 160% year-to-date but still trading at a significant discount to analysts' average price target of roughly $5.50 to $6.75, investor sentiment hangs on both financial execution and clinical progress. The Q2 print lands just weeks before the company presents first-in-human data for MGC026 — its next-generation ADC (antibody-drug conjugate) targeting B7-H3 — at the ESMO 2026 conference, making this earnings event a critical sentiment checkpoint.

Earnings Expectations

Analyst estimates for MacroGenics' Q2 2026 performance reflect a striking lack of consensus. According to data aggregated from multiple sources, revenue forecasts for the June-ending quarter range from as low as approximately $15 million to as high as $174 million, with the mean estimate clustering around $59 million to $68 million. EPS projections are similarly dispersed, with consensus estimates varying from -$0.34 to +$0.26 across different data providers. This wide range is not unusual for a clinical-stage biotechnology company where collaboration revenue, milestone payments, and royalty streams — including royalties from ZYNYZ (retifanlimab) — can create significant quarter-to-quarter lumpiness.

For context, Q2 2025 delivered revenue of $22.24 million and an EPS of -$0.57. Q1 2026 saw revenue of $20.78 million (above the $15.24 million consensus) and an EPS of -$0.58 (missed by $0.01). The market rewarded the Q1 report with a roughly 20% post-earnings stock price surge, suggesting investors are focused more on strategic execution and pipeline progress than narrowly missing bottom-line estimates.

AI Screener

Investors seeking to identify trading opportunities around earnings events like MacroGenics' Q2 release may benefit from Tickeron's AI Screener. This AI-powered stock and ETF (exchange-traded fund) discovery tool enables traders and investors to filter thousands of equities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven signals. By automating the screening process, the AI Screener helps users surface trending stocks, breakout candidates, and potential trade ideas more efficiently than traditional manual research methods, allowing market participants to stay ahead of fast-moving events like biotechnology earnings and clinical data readouts.

Market Reaction and Investor Sentiment

Heading into the Q2 2026 earnings release, MacroGenics shares have exhibited notable volatility. After starting the year trading near $1.61, the stock has rallied over 160%, recently trading in the $4.00 to $4.30 range, supported by optimism around pipeline catalysts and balance sheet strengthening. However, shares remain well below the consensus analyst price target, and the stock recently pulled back approximately 14% in a single week, reflecting lingering uncertainty. Current analyst ratings are split: three buy-equivalent ratings, three holds, and one sell, with price targets spanning from $2.00 to $9.00. Key risk factors heading into the print include the unpredictability of collaboration and royalty revenue timing, the potential for clinical trial setbacks, and broader biotech sector sentiment. The Q1 earnings beat on revenue but miss on EPS demonstrated that the market is willing to look through near-term financial noise when strategic progress is evident — a dynamic that will be tested again in Q2.

Forward Outlook and Key Factors to Monitor

Beyond the Q2 headline numbers, investors should focus on several forward-looking catalysts and operational updates likely to shape MacroGenics' trajectory through the remainder of 2026.

First, the closing of the manufacturing operations divestiture to Bora Pharmaceuticals, anticipated in Q3 2026, is expected to bring in approximately $122.5 million in proceeds (before transaction fees and expenses). Combined with the $60 million received from Sagard in April and the existing $154.2 million cash balance, MacroGenics' pro forma cash position should approach roughly $328 million, providing a runway the company expects will extend through 2028. Management commentary on the earnings call regarding the timing and use of these funds will be closely scrutinized.

Second, pipeline execution remains the central driver of long-term value. The upcoming ESMO 2026 presentation featuring first-in-human data for MGC026, the company's B7-H3-targeting ADC, represents a near-term catalyst that could materially impact investor sentiment. Additionally, the ongoing Phase 2 LORIKEET and LINNET trials evaluating lorigerlimab — a bispecific DART (Dual-Affinity Re-Targeting) molecule targeting PD-1 and CTLA-4 — in metastatic castration-resistant prostate cancer and colorectal cancer will be areas of interest for any clinical updates.

Third, the revenue trajectory will be shaped by ZYNYZ royalty growth, contract manufacturing revenue (which may be affected by the manufacturing divestiture), and the pace of milestone achievements under existing collaboration agreements with partners including Incyte and Gilead Sciences. Investors should also monitor the $24.5 million regulatory milestone payment expected from Sanofi following the FDA's accelerated approval of TZIELD for type 1 diabetes. The interplay between reduced operating expenses from the manufacturing exit and the pace of investment in the ADC and T-cell engager pipeline will ultimately determine how long the extended cash runway truly lasts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations